Regentis Receives Japanese Patent allowance, Strengthening its Global GelrinC Intellectual Property Portfolio with New Proprietary Manufacturing Technology
Regentis Biomaterials received a Notice of Allowance from the Japan Patent Office for a patent covering its proprietary organic solvent-free manufacturing process for GelrinC. The allowed patent offers a 5x increase in yield and strengthens IP protection in the Japanese cartilage repair market, which is estimated to reach $289 million by 2030. GelrinC is preparing for commercial launch in Europe and has surpassed 50% enrollment in its pivotal U.S.
Key figures
- Procedure time
- ~10-minute
- Jp market size 2030
- $289 million
- Pain relief duration
- >5 years
- Us annual cartilage cases
- 470,000
- Jp symptomatic oa patients
- 8 million
- Jp radiographic oa patients
- 25 million
- Manufacturing yield increase
- 5x
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.